| 6.06 -0.14 (-2.26%) | 01-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 7.5 | 1-year : | 8.14 |
| Resists | First : | 6.42 | Second : | 6.96 |
| Pivot price | 6.05 |
|||
| Supports | First : | 5.55 | Second : | 4.61 |
| MAs | MA(5) : | 6.26 |
MA(20) : | 6.03 |
| MA(100) : | 5.76 |
MA(250) : | 6.13 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 59.9 |
D(3) : | 71.6 |
| RSI | RSI(14): 49.1 |
|||
| 52-week | High : | 11.39 | Low : | 4.15 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ VIR ] has closed below upper band by 49.4%. Bollinger Bands are 13.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 6.26 - 6.29 | 6.29 - 6.32 |
| Low: | 5.95 - 5.99 | 5.99 - 6.03 |
| Close: | 6 - 6.06 | 6.06 - 6.11 |
Tue, 13 Jan 2026
Vir Biotechnology (NASDAQ:VIR) Trading 7.3% Higher - What's Next? - MarketBeat
Mon, 12 Jan 2026
Vir Biotechnology reports promising results for hepatitis delta therapy - Investing.com
Mon, 05 Jan 2026
Vir Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
Wed, 17 Dec 2025
Latham Advises Norgine on Exclusive Licensing Agreement With Vir Biotechnology - Latham & Watkins LLP
Wed, 17 Dec 2025
Norgine gets in on Vir's hepatitis D program with €550M European licensing pact - Fierce Biotech
Wed, 05 Nov 2025
Vir Biotechnology announces completion of enrollment in ECLIPSE 1 Phase 3 trial for chronic hepatitis delta - European AIDS Treatment Group
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 139 (M) |
| Held by Insiders | 9.772e+007 (%) |
| Held by Institutions | 10.4 (%) |
| Shares Short | 10,990 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -5.1147e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -72 % |
| Return on Assets (ttm) | 267.9 % |
| Return on Equity (ttm) | -26 % |
| Qtrly Rev. Growth | 1.686e+007 % |
| Gross Profit (p.s.) | -66.6 |
| Sales Per Share | -36.35 |
| EBITDA (p.s.) | -3.17022e+008 |
| Qtrly Earnings Growth | -3.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -454 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.17 |
| Price to Cash Flow | 1.42 |
| Dividend | 0 |
| Forward Dividend | 1.115e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|